Role of Radiotherapy for Patients with Renal-Cell Carcinoma
https://doi.org/10.37174/2587-7593-2019-2-3-5-11
Abstract
Introduction: Renal cell cancer accounts for 2 % of all cancers. The gold standard for managing patients with no evidence of distant metastasis renal cell cancer remains is complete surgical resection. Renal cell cancer is radioresistant tumor for conventional radiation therapy. Although renal cell carcinoma is related to radioresistant tumors, in recent years new promising directions in radiation therapy have become apparent.
Preoperative and postoperative irradiation: The clinical data investigating preoperative radiotherapy failed to reveal benefited from this methods. The role of routine postoperative radiotherapy in the management of renal cell cancer is not established in patients with localized disease after complete surgical resection.
Primary irradiation for localized renal cell cancer:
To overcome the radioresistance of renal cell carcinoma, the use of modified radiation therapy regimens with high doses per fraction is justified. А new technologies of radiation therapy, which include stereotactic radiation therapy (SRT) allows to accurately deliver doses of ionizing radiation to a tumor, without the risk of damage to neighboring tissues and organs.
Conclusion: Recent data showing that with the use of high-precision methods, such as SRT, unresectable local renal cell carcinoma can successfully be treated with durable local control and low toxicity. Nonetheless, prospective, randomized trials and comparative-effectiveness studies are needed to further evaluate this ablative modality in the treatment of renal cell carcinoma.
About the Authors
I. A. Gladilina
N.I. Pirogov Russian National Research Medical University; N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Moscow
M. A. Shabanov
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Moscow
E. S. Makarov
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Moscow
A. V. Egorova
N.I. Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
S. V. Chulkova
N.I. Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
References
1. Матвеев В.Б. , Маркова А.С. Рак почки: что нового в 2018 году // Онкоурология. 2018. Т. 14. № 4. C. 48-52. DOI: 10.17650/1726-9776-2018-14-4-48-52.
2. De Felice F., Tombolini V. Radiation therapy in renal cell carcinoma // Crit. Rev. Oncol. Hematol. 2018. Vol. 128. P. 82-87. DOI: 10.1016/j.critrevonc.2018.06.002. Epub 2018 Jun 12.
3. Ferlay J., Bray F., Pisani P, Parkin D.M. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. - IARC Press. Lion. 2001.
4. Давыдов М.И., Матвеев В.Б., Волкова М.И. и соавт. Хирургическое лечение больных раком почки с опухолевым тромбозом почечной и нижней полой вены // Онкоурология. 2005. № 2. С. 8-15. DOI: 10.17650/1726-9776-2017-13-1-27-36.
5. Blanco A.I., Teh B.S., Amato R.J. Role of radiation therapy in the management of renal cell cancer // Cancers (Basel). 2011. Vol. 3. № 4. P. 4010-4023. DOI: 10.3390/cancers3044010.
6. Jacobs S.C., Berg S.I., Lawson R.K. Synchronous bilateral renal cell carcinoma: total surgical excision // Cancer. 1980. Vol. 46. № 11. P 2341-2345.
7. van der Werf-Messing B. Proceedings: Carcinoma of the kidney // Cancer. 1973. Vol. 32. № 5. P. 1056-1061.
8. Tselis N., Chatzikonstantinou G. Treating the Chameleon: Radiotherapy in the management of Renal Cell Cancer // Clin. Transl. Radiat. Oncol. 2019. Vol. 16. P 7-14. DOI: 10.1016/j.ctro.2019.01.007
9. Гладилина И.А., Клеппер Л.Я., Ефимкина Ю.В. и соавт. Гипофракционированный ускоренный режим лучевой терапии у больных после органосохраняющих операций по поводу I-II стадий рака молочной железы // Опухоли женской репродуктивной системы. 2016. Т. 12. № 3. С. 17-23.
10. Juusela H., Malmio K., Alfthan O., Oravisto K.J. Preoperative irradiation in the treatment of renal adenocarcinoma // Scand. J. Urol. Nephrol. 1977. Vol. 11. № 3. P 277-281.
11. Stein M., Kuten A., Halpern J., Coachman N.M. et al. The value of postoperative irradiation in renal cell cancer // Radiother. Oncol. 1992 May. Vol. 24. № 1. P. 41-44.
12. Kjaer M., Iversen P, Hvidt V. et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group // Scand. J. Urol. Nephrol. 1987. Vol. 21. № 4. P. 285-289.
13. Makarewicz R., Zarzycka M., Kulifiska G., Windorbska W. The value of postoperative radiotherapy in advanced renal cell cancer // Neoplasma. 1998. Vol. 45. № 6. P. 380-383.
14. Каприн А.Д., Исайчев А.К. Использование дополнительных методов в лечении местнораспространенного рака почки Т3аN0M0 // Вестник РНЦРР МЗ РФ. 2006. № 6. http://vestnik.rncrr.ru/vestnik/v6/papers/isav6.htm
15. Bhatt R.S., Landis D.M., Zimmer M. et al. Hypoxia-inducible factor-2a: Effect on radiationsensitivity and differential regulation by an mTOR inhibitor // BJU Int. 2008. Vol. 102. № 3. P. 358-363. DOI: 10.1111/j.1464-410X.2008.07558.x. Epub 2008 Apr 3.
16. Deschavanne P.J., Fertil B. A review of human cell radiosensitivity in vitro // Int. J. Radiat. Oncol. Biol. Phys. 1996. Vol. 34. № 1. P. 251-266.
17. Hui Z., Tretiakova M., Zhang Z. et al. Radiosensitization by inhibiting STAT1 in renal cell carcinoma // Int. J. Radiat. Oncol. Biol. Phys. 2009. Vol. 73. № 1. P 288-295. DOI: 10.1016/j.ijrobp.2008.08.043.
18. Ning S., Trisler K., Wessels B.W., Knox S.J. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts // Cancer. 1997. Vol. 80. № 12. Suppl. P 2519-2528.
19. Walsh L., Stanfield J.L., Cho L.C., Chang C.H. Efficacy of ablative high-dose per-fraction radiation for implanted human renal cell cancer in a nude mouse model // Eur. Urol. 2006. Vol. 50. № 4. P 795-800; discussion 800. Epub 2006 Mar 29.
20. Swaminath A., Chu W. Stereotactic body radiotherapy for the treatment of medically inoperable primary renal cell carcinoma: Current evidence and future directions // Can. Urol. Assoc. J. 2015. Vol. 9. № 7-8. P. 275-280. DOI: 10.5489/cuaj.2900.
21. Siva S., Kothari G., Muacevic A., Louie A.V. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach // Natl. Rev. Urol. 2017. Vol. 14. № 9. P 549563. DOI: 10.1038/nrurol.2017.87. Epub 2017 Jun 20.
22. Siva S., Pham D., Gill S., Corcoran N.M. et al. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma // BJU Int. 2012. Vol. 110. № 11 Pt B. P. E737-743. DOI: 10.1111/j.1464-410X.2012.11550.x. [Epub 2012 Oct 29].
23. Wersall P.J., Blomgren H., Lax I., Kalkner K.-M. et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma // Radiother. Oncol. 2005. Vol. 77. № 1. P. 88-95. Epub 2005 Jun 20.
24. Siva S., Pham D.J., Tan T.H. et al. Principal analysis of a phase Ib trial of stereotactic body radiation therapy (SBRT) for primary kidney Cancer // Int. J. Radiat. Oncol. Biol. Phys. 2016. Vol. 96. № 2S. P S96.
25. Siva S., Louie A.V., Warner A. et al. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK) // Cancer. 2018. Vol. 124. № 5. P 934-942. DOI: 10.1002/cncr.31156. Epub 2017 Dec 20.
26. Siva S., Chesson B., Bressel M. et al. TROG 15.03 phase II clinical trial of focal ablative stereotactic radiosurgery for cancers of the kidney - FASTRACK II // BMC Cancer. 2018. Vol. 18. № 1. P. 1030. DOI: 10.1186/s12885-018-4916-2.
27. Qian G., Lowry J., Silverman P. et al. Stereotactic extracranial radiosurgery for renal cell carcinoma // Int. J. Radiat. Oncol. Biol. Phys. 2003. Vol. 57. Suppl. 2. S283.
28. Svedman C., Sandstrom P, Pisa P et al. A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma // Acta Oncol. 2006. Vol. 45. № 7. P. 870-875.
29. Gilson B., Lederman G., Qian G., Fastaia M. et al. Hypo-fractionated stereotactic extra-cranial radiosurgery (HFSR) for primary and metastatic renal cell carcinoma // Int. J. Radiat. Oncol. 2006. Vol. 66. P. S349. DOI: 10.1016/j.ijrobp.2006.07.656
30. Teh B., Bloch C., Galli-Guevara M., Doh L. et al. The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT) // Biomed. Imaging Interv. J. 2007. Vol. 3. № 1. P. e6. DOI: 10.2349/biij.3.1.e6. Epub 2007 Jan 1.
31. Svedman C., Karlsson K., Rutkowska E., Sandstrom P. et al. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney // Acta Oncol. 2008. Vol. 47. № 8. P. 1578-1583. DOI: 10.1080/02841860802123196.
32. Nomiya T., Tsuji H., Hirasawa N., Kato H. et al. Carbon ion radiation therapy for primary renal cell carcinoma: Initial clinical experience // Int. J. Radiat. Oncol. Biol. Phys. 2008. Vol. 72. № 3. P. 828-833. DOI: 10.1016/j.ijrobp.2008.01.043. Epub 2008 Apr 18.
33. Nair V.J., Szanto J., Vandervoort E., Cagiannos I. et al. Cyberknife for inoperable renal tumours: Canadian pioneering experience // Can. J. Urol. 2013. Vol. 20. № 5. P. 6944-6949.
34. McBride S.M., Wagner A.A., Kaplan I.D. A phase 1 dose-escalation study of robotic radiosurgery in inoperable primary renal cell carcinoma // Int. J. Radiat. Oncol. Biol. Phys. 2013. Vol. 87. № 2. P S84.
35. Wang Y.J., Han T.T., Xue J.X., Chang D.S. et al. Stereotactic gamma-ray body radiation therapy for asynchronous bilateral renal cell carcinoma // Radiol. Med. 2014. Vol. 119. № 11. P. 878-883. DOI: 10.1007/s11547-014-0402-3. Epub 2014 Apr 3.
36. Lo C.H., Huang W.Y., Chao H.L., Lin K.T. et al. Novel application of stereotactic ablative radiotherapy using CyberKnife for early-stage renal cell carcinoma in patients with preexisting chronic kidney disease: initial clinical experiences // Oncol. Lett. 2014. Vol. 8. № 1. P. 355-360. Epub 2014 May 9.
37. Pham D., Thompson A., Kron T., Foroudi F. et al. Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity // Int. J. Radiat. Oncol. Biol. Phys. 2014. Vol. 90. № 5. P. 1061-1068. DOI: 10.1016/j.ijrobp.2014.07.043. Epub 2014 Oct 13.
38. Staehler M., Bader M., Schlenker B., Casuscelli J. et al. Single fraction radiosurgery for the treatment of renal tumors // J. Urol. 2015. Vol. 194. № 4. P 1165; discussion 1166-1167. DOI: 10.1016/j.juro.2015.04.085. Epub 2015 Jul 3.
39. Ponsky L., Lo S.S., Zhang Y., Schluchter M. et al. Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma // Radiother. Oncol. 2015. Vol. 117. № 1. P. 183-187. DOI: 10.1016/j.radonc.2015.08.030. Epub 2015 Sep 8.
40. Chang J.H., Cheung P., Erler D., Sonier M. et al. Stereotactic ablative body radiotherapy for primary renal cell carcinoma in non-surgical candidates: initial clinical experience // Clin. Oncol. (R. Coll. Radiol). 2016. Vol. 28. № 9. P. e109-14. DOI: 10.1016/j.clon.2016.04.002. Epub 2016 Apr 27.
Review
For citations:
Gladilina I.A., Shabanov M.A., Makarov E.S., Egorova A.V., Chulkova S.V. Role of Radiotherapy for Patients with Renal-Cell Carcinoma. Journal of oncology: diagnostic radiology and radiotherapy. 2019;2(3):5-11. (In Russ.) https://doi.org/10.37174/2587-7593-2019-2-3-5-11
Views:
1080
Email this article 